S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
OVID · Ovid Therapeutics Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Ovid Therapeutics Inc (OVID)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.48
+0.13
(+5.74%)
● At close: October 21 at 4:00:00 PM EDT
$2.50
+0.03
(+1.21%)
Overnight:
10:03:36 PM EDT
DAY'S RANGE
$2.48
$2.35
$2.65
52-WEEK RANGE
$2.48
$1.18
$3.10
What's happening
- OVID is up 5.74% today, trading at $2.48. — Live quote
- Volume today (450,671) is well below its 3-month average of 2,103,610. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.08 actual vs. $-0.12 estimated (+35.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
OVID
+44.79%
vs S&P 500
+32.01%
1-YEAR RETURN
OVID
+43.03%
vs S&P 500
+28.47%
6-MONTH RETURN
OVID
-15.71%
3-MONTH RETURN
OVID
-2.07%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.08
Est. $-0.12
BEAT +35.2%
2026-04-26 (Q1 2026)
$-0.12
Est. $-0.12
BEAT +2.2%
2026-01-26 (Q4 2025)
$0.06
Est. $-0.12
BEAT +149.4%
2025-10-26 (Q3 2025)
$-0.17
Est. $-0.15
MISS -11.2%
Valuation Measures & Ratios
Enterprise Value4$453.5M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)293.63
Price / Book72.39
EV4 / Revenue286.47
EV4 / EBITDA3.65
Profit Margin-1105.75%
Operating Margin-2559.32%
Return on Equity (ROE8)-23.64%
Return on Assets (ROA9)-20.52%
Avg Volume (3M)2,103,610
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short18,948,082
Change from Prior Settlement-10.42%
% of Float—
Days to Cover (Short Ratio)8.93
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +43.0%. Finnhub market metrics ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -88.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -1105.8%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on OVID
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $733.0K | $0 | $132.0K | $6.3M | $130.0K | $173.0K | $169.0K | $148.0K |
| Operating income | -$15.7M | -$17.8M | -$12.5M | -$5.1M | -$12.6M | -$13.2M | -$20.5M | -$17.4M |
| Net income | -$15.0M | -$17.0M | -$12.2M | -$4.7M | -$10.2M | -$14.0M | $8.5M | -$11.7M |
| EPS (diluted) | — | — | — | — | — | $-0.20 | $0.12 | $-0.17 |
| EPS (basic) | — | — | — | — | — | $-0.20 | $0.12 | $-0.17 |
| Operating margin | -$2.1K | — | -$9.5K | -$81 | -$9.7K | -$7.6K | -$12.1K | -$11.8K |
| Net margin | -$2.0K | — | -$9.2K | -$75 | -$7.9K | -$8.1K | $5.0K | -$7.9K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $232.0M | $225.6M | $150.9M | $63.8M | $77.4M | $81.7M | $92.2M | $102.7M |
| Total liabilities | $22.1M | $27.4M | $20.3M | $19.1M | $21.6M | $22.4M | $23.9M | $26.4M |
| Stockholders' equity | $209.9M | $198.3M | $130.7M | $44.7M | $55.8M | $59.3M | $68.2M | $76.3M |
| Total current assets | $123.6M | $160.1M | $74.4M | $28.8M | $42.1M | $45.9M | $55.9M | $65.8M |
| Total current liabilities | $10.0M | $15.7M | $8.3M | $6.8M | $8.9M | $9.3M | $10.5M | $11.6M |
| Cash & equivalents | $11.3M | $94.1M | $13.2M | $20.6M | $28.4M | $21.1M | $26.3M | $15.0M |
| Marketable securities (non-current) | — | — | — | $20.9M | $20.9M | $20.9M | $21.0M | $21.1M |
| Property, plant & equipment | $201.0K | $217.0K | $252.0K | $269.0K | $285.0K | $346.0K | $433.0K | $509.0K |
| Intangible assets | $0 | $0 | $0 | $0 | $0 | $38.0K | $100.0K | $155.0K |
| Other non-current assets | — | — | $0 | $0 | $0 | $39.0K | $92.0K | $182.0K |
| Accounts payable | $4.1M | $8.9M | $2.0M | $1.7M | $4.0M | $1.9M | $3.2M | $2.7M |
| Accrued liabilities | $4.4M | $5.4M | $4.9M | $3.0M | $2.9M | $6.0M | $6.0M | $7.6M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $185.0K | $167.0K | $130.0K | $71.0K | $71.0K | $71.0K | $71.0K | $71.0K |
| Retained earnings | -$353.7M | -$338.7M | -$321.7M | -$331.4M | -$319.2M | -$314.5M | -$304.3M | -$295.0M |
| Accumulated other comprehensive income (loss) | -$750.0K | -$422.0K | -$202.0K | -$126.0K | -$69.0K | -$47.0K | -$35.0K | $36.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.6M | -$13.9M | -$10.4M | -$12.9M | -$4.8M | -$10.3M | -$10.0M | -$15.0M |
| Investing cash flow | -$86.7M | $6.0M | -$72.1M | $5.1M | $12.1M | $5.1M | $21.3M | $292.0K |
| Financing cash flow | $21.6M | $89.0M | $75.2M | $15.0K | $0 | $13.0K | $0 | $38.0K |
| Free cash flow | — | — | -$10.4M | -$12.9M | -$4.8M | -$10.3M | -$10.0M | -$15.0M |
| Capital expenditures | — | — | $0 | $0 | $0 | $0 | $22.0K | -$4.0K |
| Depreciation & amortization | $16.0K | $35.0K | $17.0K | $16.0K | $99.0K | $141.0K | $160.0K | $169.0K |
| Share-based compensation | $1.4M | $1.0M | $1.2M | $1.1M | $1.2M | $1.3M | $1.3M | $1.3M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Purchases of investments | $102.7M | $4.0M | $77.1M | $4.9M | $4.9M | $4.9M | $16.7M | $9.7M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $7.3M | $566.0K | $392.0K | $1.5M | $208.4M |
| Operating income | -$42.4M | -$61.9M | -$59.3M | -$55.5M | $124.2M |
| Net income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | $122.8M |
| EPS (diluted) | — | — | $-0.74 | $-0.77 | $1.76 |
| EPS (basic) | — | — | $-0.74 | $-0.77 | $1.78 |
| Operating margin | -$585 | -$10.9K | -$15.1K | -$3.7K | $60 |
| Net margin | -$240 | -$4.7K | -$13.4K | -$3.6K | $59 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $150.9M | $92.2M | $144.0M | $155.3M | $194.5M |
| Total liabilities | $20.3M | $23.9M | $56.2M | $23.0M | $14.8M |
| Stockholders' equity | $130.7M | $68.2M | $87.8M | $132.3M | $179.7M |
| Total current assets | $74.4M | $55.9M | $109.6M | $131.4M | $190.5M |
| Total current liabilities | $8.3M | $10.5M | $11.5M | $7.0M | $14.8M |
| Cash & equivalents | $13.2M | $26.3M | $27.0M | $44.9M | $187.8M |
| Marketable securities (non-current) | — | $21.0M | $17.6M | $5.6M | $1.6M |
| Property, plant & equipment | $252.0K | $433.0K | $769.0K | $1.1M | $242.8K |
| Intangible assets | $0 | $100.0K | $200.0K | $222.1K | $164.1K |
| Other non-current assets | $0 | $92.0K | $210.0K | $261.2K | $260.1K |
| Accounts payable | $2.0M | $3.2M | $3.7M | $2.0M | $7.1M |
| Accrued liabilities | $4.9M | $6.0M | $6.5M | $4.5M | $7.7M |
| Deferred revenue (current) | — | — | — | — | $0 |
| Common stock & paid-in capital | $130.0K | $71.0K | $71.0K | $70.5K | $70.4K |
| Retained earnings | -$321.7M | -$304.3M | -$277.9M | -$225.5M | -$171.4M |
| Accumulated other comprehensive income (loss) | -$202.0K | -$35.0K | $1.0K | -$42.2K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$38.3M | -$56.0M | -$45.8M | -$55.2M | $118.6M |
| Investing cash flow | -$49.9M | $54.6M | -$2.6M | -$87.9M | -$1.8M |
| Financing cash flow | $75.2M | $622.0K | $30.5M | $180.7K | $904.1K |
| Free cash flow | -$38.3M | -$56.0M | -$45.8M | -$56.5M | $118.4M |
| Capital expenditures | $0 | $71.0K | $40.0K | $1.2M | $184.0K |
| Depreciation & amortization | $273.0K | $613.0K | $568.0K | $512.5K | $237.1K |
| Share-based compensation | $4.8M | $6.3M | $7.3M | $6.6M | $5.1M |
| Deferred income taxes | — | — | — | — | — |
| Purchases of investments | $91.9M | $73.2M | $112.4M | $173.0M | $0 |
| Sales/maturities of investments | — | — | — | — | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding OVID as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-02-26 to 2026-07-06
Recent transactions
- Most recent: Carter Charles Ross (Chief Financial Officer) — Grant / award of 50,000 shares on 2026-07-06.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Carter Charles Ross | Chief Financial Officer | Grant / award | 2026-07-06 | 50,000 |
| PAPADOPOULOS STELIOS | Reporting person | Grant / award | 2026-04-07 | 17,578 |
| Friedman Bart | Reporting person | Grant / award | 2026-04-07 | 8,789 |
| Fitzgerald Kevin Joseph | Reporting person | Grant / award | 2026-04-07 | 17,578 |
| LEVIN JEREMY M | Executive Chairman | Option exercise | 2026-03-23 | 47,333 |
| Rona Jeffrey A | CBFO | Grant / award | 2026-02-26 | 68,125 |
| ALEXANDER MARGARET A. | President and CEO | Open market sale | 2026-02-23 | 11,656 |
| TAKEDA PHARMACEUTICAL CO LTD | 10% owner | Derivative conversion | 2025-12-08 | 1,250,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-06 | Carter Charles Ross | Chief Financial Officer | Grant / award | 50,000 | $0.00 |
| 2026-04-07 | PAPADOPOULOS STELIOS | Reporting person | Grant / award | 17,578 | $2.56 |
| 2026-04-07 | Friedman Bart | Reporting person | Grant / award | 8,789 | $2.56 |
| 2026-04-07 | Fitzgerald Kevin Joseph | Reporting person | Grant / award | 17,578 | $2.56 |
| 2026-03-23 | LEVIN JEREMY M | Executive Chairman | Option exercise | 47,333 | $1.40 |
| 2026-02-26 | Rona Jeffrey A | CBFO | Grant / award | 68,125 | $0.00 |
| 2026-02-23 | ALEXANDER MARGARET A. | President and CEO | Open market sale | 11,656 | $1.45 |
| 2026-02-23 | Rona Jeffrey A | CBFO | Open market sale | 8,541 | $1.45 |
| 2025-12-15 | LEVIN JEREMY M | CEO | Derivative conversion | 71,000 | — |
| 2025-12-08 | TAKEDA PHARMACEUTICAL CO LTD | 10% owner | Derivative conversion | 1,250,000 | $0.00 |
| 2025-02-26 | ALEXANDER MARGARET A. | President and COO | Open market sale | 5,279 | $0.56 |
| 2025-02-26 | Rona Jeffrey A | CBFO | Open market sale | 3,902 | $0.56 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:19 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-07-08 | 8-K | 2026-07-05 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-06-03 | 8-K | 2026-05-29 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-04-20 | 8-K | 2026-04-17 | View on SEC.gov → |
| 2026-04-09 | 4 | 2026-04-07 | View on SEC.gov → |
| 2026-04-09 | 4 | 2026-04-07 | View on SEC.gov → |
Recent news
Headlines about OVID (Ovid Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
OVID Apr 2027 2.000 call (OVID270416C00002000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18 -
OVID Initiates Coverage On Wolfe Research -- Rating Set to Outpe
GuruFocus · 2026-10-15 -
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
Yahoo · 2026-10-15 -
Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5
Benzinga · 2026-10-15 -
Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating
Benzinga · 2026-10-09 -
Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329
Yahoo · 2026-10-08 -
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Yahoo Finance · 2026-09-03 -
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Yahoo Finance · 2026-08-18
No headlines in this category right now — try “All”.